Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 13/20 | 0.68 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.66 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.66 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL225017 | 0.98 | PSMB1 (0.69) | LTA4HPSMB1PSMB5PSMB2HRH3 | |
| SCHEMBL27593 | 0.98 | PSMB1 (0.69) | LTA4HPSMB1PSMB5PSMB2HRH3 | |
| Hydrochloric Acid SCHEMBL5685583 | 0.97 | PSMB1 (0.67) | LTA4HPSMB1PSMB5PSMB2HRH3 | |
| SCHEMBL2005536 | 0.92 | HRH3 (0.67) | HRH3KDM4E | |
| SCHEMBL30409990 | 0.90 | HRH3 (0.65) | HRH3KDM4E | |
| SCHEMBL491848 | 0.90 | HRH3 (0.69) | HRH3 | |
| SCHEMBL30409967 | 0.89 | MEN1 (0.66) | HRH3 | |
| SCHEMBL30411052 | 0.89 | HRH3 (0.68) | HRH3 | |
| Hydrochloric Acid SCHEMBL5692315 | 0.89 | HRH3 (0.68) | HRH3 | |
| SCHEMBL30410512 | 0.89 | MEN1 (0.66) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2020-07-23 | — | — | US | disclosed |
| US-10669257-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3599236-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2020-01-29 | — | — | EP | disclosed |
| EP-3202460-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20190135780-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2019-05-09 | — | — | US | disclosed |
| EP-3106460-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-1996009051-A1 | A METHOD FOR MINIMIZING THE UTEROTROPHIC EFFECT OF TAMOXIFEN AND TAMOXIFEN ANALOGS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| EP-0702962-A2 | Preparations for inhibiting mammalian breast carcinoma with tamoxifen and analogs thereof, and certain naphthyl compounds | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0703228-A1 | Naphthyl compounds, intermediates, processes, compositions involving them | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
| EP-0702961-A2 | Compositions for minimizing the uterotrophic effect of tamoxifen and its analogs | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
| US-5496844-A | Indole derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0639567-A1 | INDOLE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1995-02-22 | — | — | EP | disclosed |
| EP-0306827-B1 | AMIDE COMPOUNDS, PROCESS FOR PREPARING THE SAME, AND COMPOSITION FOR ACTIVATING GASTRIC MOTOR FUNCTION CONTAINING THE SAME | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1991-09-04 | — | — | EP | disclosed |
| US-4983633-A | Amide compounds, process for preparing the same, and composition for activating gastric motor function containing the same | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1991-01-08 | — | — | US | disclosed |
| EP-0306827-A1 | Amide compounds, process for preparing the same, and composition for activating gastric motor function containing the same | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1989-03-15 | — | — | EP | disclosed |
| US-4336374-A | HYPOGLYCEMIC AGENTS | NIPPON SHINYAKU CO., LTD. (JP) | 1982-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669257-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | LTA4H 2027/4885PSMB1 3380/4885PSMB5 1972/4885 |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | LTA4H 2027/4885PSMB1 3380/4885PSMB5 1972/4885 |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | LTA4H 2027/4885PSMB1 3380/4885PSMB5 1972/4885 |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | LTA4H 2027/4885PSMB1 3380/4885PSMB5 1972/4885 |
| US-20190135780-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | LTA4H 2027/4885PSMB1 3380/4885PSMB5 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.